J. Fischer

发表

The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment

S. Reingold, J. Fischer, R. Rudick, 1999, Multiple sclerosis.

Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

Stephen M. Rao, S. Reingold, A. Thompson, 1999, Brain : a journal of neurology.

Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis

Jeanelle Sheeder, C. Granger, R. Herndon, 1998 .

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

C. Granger, R. Herndon, R. Kinkel, 1996, Annals of neurology.

A longitudinal study of T1 hypointense lesions in relapsing MS

J H Simon, R. Herndon, R. Kinkel, 2000, Neurology.

Minimal Neuropsychological Assessment of MS Patients: A Consensus Approach

Ralph H B Benedict, Stephen M. Rao, John D Fisk, 2002, The Clinical neuropsychologist.

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997.

R. Kinkel, J. Fischer, R. Rudick, 1997, Neurology.

Benefit of interferon &bgr;-1a on MSFC progression in secondary progressive MS

Jeffrey A. Cohen, J. Fischer, R. Rudick, 2002, Neurology.

Cognitive Impairment in Multiple Sclerosis

J. Fischer, 2001 .

Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

C. Granger, R. Kinkel, J. Fischer, 1999, Journal of neuroimmunology.

Multiple Sclerosis Quality of Life Inventory

Deborah M. Miller, D. Paty, J. Fischer, 2021 .

Treatment of Multiple Sclerosis with Methotrexate

J. Fischer, D. Goodkin, 1996 .

Low‐dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis

S. Medendorp, J. Fischer, R. Rudick, 1995, Annals of neurology.

The Goldman Consensus statement on depression in multiple sclerosis

Deborah M. Miller, D. Mohr, R. Schiffer, 2005, Multiple sclerosis.

Assessing Depressive Symptoms in Multiple Sclerosis: Is It Necessary to Omit Items from the Original Beck Depression Inventory?

J. L. Taylor, J. Fischer, N. Pliskin, 1999, Journal of Behavioral Medicine.

Orgasm phase dysfunctions in multiple sclerosis

J. Fischer, L. Schover, A. Thomas, 1988 .

Neuropsychological effects of interferon β‐1a in relapsing multiple sclerosis

J. Grafman, C. Granger, M. Lezak, 2000 .

Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group.

J. Grafman, C. Granger, M. Lezak, 2000, Annals of neurology.

Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life.

Deborah M. Miller, J. Fischer, R. Rudick, 2000, Archives of neurology.

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

J. Fischer, G. Cutter, J. Simon, 2001, Archives of neurology.

Intrarater and interrater reliability of the MS functional composite outcome measure

J. Fischer, G. Cutter, A. Jak, 2000, Neurology.

Recommendations from the national multiple sclerosis society clinical outcomes assessment task force

Christian Confavreux, John Petkau, Karl Syndulko, 1997, Annals of neurology.

Clinical outcomes assessment in multiple sclerosis

Christian Confavreux, Alan Thompson, Stephen M. Rao, 1996, Annals of neurology.

Using the wechsler memory scale-revised to detect and characterize memory deficits in multiple sclerosis

J. Fischer, 1988 .

Quality of life in 1000 patients with early relapsing–remitting multiple sclerosis

J. Fischer, N. Putzki, H. Hartung, 2009, European journal of neurology.

“Quality of Life” Assessment in Multiple Sclerosis Clinical Trials: Current Status and Strategies for Improving Multiple Sclerosis Clinical Trial Design

Deborah M. Miller, D. Paty, J. Fischer, 1996 .

What Do We Really Know About Cognitive Dysfunction, Affective Disorders, and Stress in Multiple Sclerosis? A Practitioner's Guide

Stephen M. Rao, J. Fischer, F. Foley, 1994 .

Recent developments in the assessment of quality of life in Multiple Sclerosis (MS)

Deborah M. Miller, D. Paty, J. Fischer, 1999, Multiple sclerosis.

A Replicated Prospective Investigation of Life Stress, Coping, and Depressive Symptoms in Multiple Sclerosis

J. Fischer, R. Rudick, J. Aikens, 2004, Journal of Behavioral Medicine.

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis

R. P. Kinkel, D. L. Cookfair, R. Herndon, 1997, Neurology.

Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis 1 Studies supported by the National Multiple Sclerosis Society (grants RG2019, RG2827); the NINDS (NS26321); and Biogen Inc. 1

C. Granger, R. Herndon, R. Kinkel, 1999, Journal of Neuroimmunology.

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

J H Simon, A L Scherzinger, C. Granger, 1998, Annals of neurology.

Use of Neuropsychologic Outcome Measures in Multiple Sclerosis Clinical Trials: Current Status and Strategies for Improving Multiple Sclerosis Clinical Trial Design

J. Fischer, 1996 .

Cognitive Impairment in Multiple Sclerosis

J. Fischer, 2001 .

Multiple sclerosis progression in a natural history study: Predictive value of cerebrospinal fluid free kappa light chains

J. Fischer, R. Rudick, J. Fischer, 1995, Multiple sclerosis.

A longitudinal study of brain atrophy in relapsing multiple sclerosis

R. Herndon, R. Kinkel, J. Fischer, 1999, Neurology.